Print

Purpose

The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥ 18 years - Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1. - Metastatic histologically or cytologically confirmed pancreatic ductal adenocarcinoma. - Have metastatic disease - Must not have received prior systemic treatment for pancreatic cancer. - Have measurable disease based on RECIST 1.1. - Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures. - Women of childbearing potential (WOCBP) must have a negative serum pregnancy test. - For both Women and Men, must use acceptable form of birth control while on study. - Must understand the study regimen, its requirements, risks and discomforts and is able and willing to sign the informed consent form in accordance with regulatory and institutional guidelines.

Exclusion Criteria

  • Have had prior chemotherapy for pancreatic cancer or prior chemotherapy within 5 years of enrollment for other cancer diagnoses. - Has received radiotherapy for pancreatic cancer. - Are receiving or have received any investigational agent or used an investigational device within 28 days prior to Day 1 of treatment in this study. - Has undergone major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis or an aborted Whipple), within 28 days prior to Day 1 of treatment in this study. - Is expected to require any other form of systemic or localized antineoplastic therapy while on study. - Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, or anti-Lag-3 antibodies. - Has received a live vaccine or live-attenuated vaccine within 28 days prior to the first dose of study drug. - Prior tissue or organ allograft regardless of need for immunosuppression, including corneal allograft. - Has uncontrolled acute or chronic medical illness. - Has history of central nervous system (CNS) metastases and/or carcinomatous meningitis. - Has known additional malignancy that is progressing and requires active treatment. - Has active autoimmune disease. - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent). - Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. - Requirement for daily supplemental oxygen. - History of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases, chronic obstructive pulmonary disease (COPD), asthma requiring medication, etc. - Known history of human immunodeficiency virus (HIV). - Active or chronic hepatitis B or hepatitis C. - Unable to undergo venipuncture and/or tolerate venous access. - Has known psychiatric or substance use disorder that would interfere with cooperation with the requirements of the trial. - Pregnant or breastfeeding - A WOCBP who has a positive urine pregnancy test within 72 hours prior to study drug initiation.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm 1 - FOLFIRINOX/NC410/Nivolumab
  • Drug: Oxaliplatin
    65mg/m2 will be administered as a 120 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
  • Drug: Irinotecan
    150 mg/m2 will be administered as a 90 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
  • Drug: Folinic Acid
    50 mg will be administered as a 15 minute IV infusion (-5/+20 min) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. Folinic acid can be given concurrent with irinotecan. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
  • Drug: 5-Fluorouracil (5-FU)
    2400 mgm2 will be administered as a continuous IV Infusion (-120/+ 120 minutes) over approximately 46 hours on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
  • Drug: NC410
    100 mg will be administered as a 60 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
    Other names:
    • NextCure LAIR-2 fusion protein
  • Drug: Nivolumab
    400 mg will be administered as a 30 minute IV Infusion (-5/+20 minutes) once on Cycle 1 Day 1. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
    Other names:
    • OPDIVO
Experimental
Arm 2 - FOLFIRINOX/NC410/Nivolumab/Ipilimumab
  • Drug: Oxaliplatin
    65mg/m2 will be administered as a 120 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
  • Drug: Irinotecan
    150 mg/m2 will be administered as a 90 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
  • Drug: Folinic Acid
    50 mg will be administered as a 15 minute IV infusion (-5/+20 min) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. Folinic acid can be given concurrent with irinotecan. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
  • Drug: 5-Fluorouracil (5-FU)
    2400 mgm2 will be administered as a continuous IV Infusion (-120/+ 120 minutes) over approximately 46 hours on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
  • Drug: NC410
    100 mg will be administered as a 60 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
    Other names:
    • NextCure LAIR-2 fusion protein
  • Drug: Nivolumab
    400 mg will be administered as a 30 minute IV Infusion (-5/+20 minutes) once on Cycle 1 Day 1. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
    Other names:
    • OPDIVO
  • Drug: Ipilimumab
    50 mg will be administered as a 30 minute IV Infusion (-5/+20 minutes) once on Cycle 1 Day 1. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
    Other names:
    • YERVOY

Recruiting Locations

Sidney Kimmel Comprehensive Cancer Center
Baltimore 4347778, Maryland 4361885 21231
Contact:
Colleen Apostol, RN
410-614-3644
GIClinicalTrials@jhmi.edu

More Details

Status
Recruiting
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Contact

Colleen Apostol, RN
410-614-3644
GIClinicalTrials@jhmi.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.